OrbiMed’s Ventyx Biosciences VTYX Stock Holding History

OrbiMed’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,870,456	Closed	-$10.3M	–	124
2024 Q1	$10.3M	Buy	+1,870,456	New	+$8.55M	0.19%	79
2023 Q4	–	Sell	-340,384	Closed	-$11.8M	–	133
2023 Q3	$11.8M	Sell	340,384 -200,600	-37%	-$6.94M	0.25%	77
2023 Q2	$17.7M	Sell	540,984 -44,016	-8%	-$1.52M	0.32%	74
2023 Q1	$19.6M	Sell	585,000 -340,000	-37%	-$13.2M	0.38%	68
2022 Q4	$30.3M	Buy	925,000 +700,000	+311%	+$20.7M	0.58%	57
2022 Q3	$7.86K	Sell	225,000 -1,064,280	-83%	-$23.6M	0.15%	92
2022 Q2	$15.8K	Hold	1,289,280	–	–	0.29%	74
2022 Q1	$17.5M	Hold	1,289,280	–	–	0.28%	71
2021 Q4	$25.6M	Buy	+1,289,280	New	+$24.4M	0.33%	74

Other funds holding VTYX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's VTYX Position: Q2 2024 in Review

OrbiMed sold out of Ventyx Biosciences (VTYX) in Q2 2024, closing a stake of 1,870,456 shares — an estimated $10.3M sold.

OrbiMed first reported a position in VTYX in Q4 2021 and held it in 9 quarters. The position peaked at $30.3M in Q4 2022. 117 funds tracked by Wall St. Rank hold VTYX as of Q2 2024.

OrbiMed reported no remaining Ventyx Biosciences position as of Q2 2024 after selling out during the quarter.
OrbiMed sold 1,870,456 Ventyx Biosciences shares in Q2 2024, an estimated $10.3M.
OrbiMed first reported a position in Ventyx Biosciences in Q4 2021 and held it in 9 quarters.
OrbiMed's Ventyx Biosciences position peaked at $30.3M in Q4 2022.
117 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2024.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.